Repligen's Record Quarter Is a 2027 Story Wearing a 2026 Disguise
Record revenue and a raised guide validate the recovery trade — but the capital-equipment 'tap' is still only 5-10% open, and the stock has already run 39% in 90 days.
RGEN · Earnings Call · 2026-10-27
Repligen's third quarter arrived with the stock already moving. Shares are up 38.9% over the last 90 trading days and sit within 9.6% of their recent high, even though the full history still shows a 45.8% drawdown from the 2021 peak. That is a market that has pre-paid for a bioprocessing recovery. The report largely validates the optimism — record revenue, a raised guide, and the BioLife acquisition closing — but it also exposes the same awkward gap that has defined this cycle: orders are returning before revenue.
A record quarter with a capital-equipment asterisk
The headline is genuinely strong. Revenue hit $209 million, 12.5% organic growth, and adjusted operating margin expanded 170 basis points. Consumables grew 20%, services more than 20%, chromatography more than 50%, proteins more than 40%, and analytics 20%. The laggard was filtration, down 11% on the anticipated gene-therapy headwind, two ATF customer inventory/site issues, and the PolyMem divestiture. Management called it a record quarter and a proof point that the industry is entering its next growth phase: “We had a record quarter with $209 million of revenue. This is a significant milestone as we surpassed our prior peak in the second quarter of 2022.” — Olivier Loeillot, President and Chief Executive Officer · 2026-10-27
But the equipment recovery is still a promissory note. Capital-equipment orders rose mid-teens year over year and were the highest in five years, yet equipment revenue declined. The orders are real; the revenue is not yet. On the Q&A, Olivier Loeillot was blunt about timing: “We probably will not recognize a lot of it this year. it is all sitting in 2027.” — Olivier Loeillot, President and Chief Executive Officer · 2026-10-27
Capital equipment orders increased mid-teens year-over-year and was the highest orders quarter in 5 years while revenue declined. The tap has not opened as quickly as we would have expected this year.
That metaphor is not new. In May, management said “the water is just waiting for the tap to open” — Olivier Loeillot, President and Chief Executive Officer · 2026-05-05, and in July it was “starting to build a really nice backlog for ’27” — Olivier Loeillot, President and Chief Executive Officer · 2026-07-28. What changed this quarter is the order level itself — the highest since 2021 — and the confidence that filtration returns to historical growth in 2027. What did not change is customer decision velocity. The integrated solution team and the equipment side are still waiting on large pharma to commit capital. Onshoring remains the biggest swing factor, and management now says it is nine to twelve months delayed versus its own expectations, consistent with the February comment that onshoring projects “tend to still be pushed out until 2027.” — Jason Garland, CFO · 2026-02-24
BioLife: buying the cell-therapy answer
The strategic pivot is the BioLife acquisition, which closed October 6 for roughly $550 million of cash, net of cash received. Repligen expects about $24 million of BioLife revenue in Q4, a 2026 pro forma run rate of about $114 million, and 2027 total revenue above $1 billion with at least 25% reported growth. BioLife is slightly dilutive to Q4 EPS but expected to be at least $0.05 accretive in 2027. More than half of the anticipated Year 1 operating-expense synergies are already actioned, and the team is evaluating CryoStor scrap rates for gross-margin upside.
The interesting part is how conservative the deal model is on cell therapy. Management assumed no FDA approvals for the first two years after closing, yet three cell therapies have already been approved this year. Loeillot framed it plainly: “there could be no FDA approval of cell therapy for the first 2 years after we acquired the business.” — Olivier Loeillot, President and Chief Executive Officer · 2026-10-27 If the commercial cell-therapy market keeps growing above 20%, that assumption becomes a source of upside rather than a cushion. The risk is that Repligen is buying into a modality that has repeatedly promised more than it delivered; the reward is that it now owns a broader platform in the fastest-growing part of new modalities.
China and the protein-concentration wedge
China was the other standout. Revenue grew more than 40% in the quarter and more than 50% year to date, and Asia Pacific orders set a record. Management highlighted China's new five-year biotech plan, which targets more than 20% CAGR through 2030. That is a large number to hang on a region that was only 2-3% of sales a year ago, but the direction is clear: Repligen is investing in local manufacturing and partnerships rather than ceding the market to domestic competitors.
The quieter, more company-specific catalyst is protein concentration. The USP Chapter 507 standard recently recognized Repligen's SoloVPE PLUS technology, which should lower adoption barriers and support FlowVPX pull-through. Management said 75-80% of systems sold now include a FlowVPX attachment. That is a real competitive moat in downstream equipment, and it explains why analytics is expected to grow more than 30% this year even against a tough comparison. As Loeillot put it: “USP chapter 507 recently recognized our SoloVPE PLUS technology as being really the technology which is aligned with the official standard to measure protein concentration.” — Olivier Loeillot, President and Chief Executive Officer · 2026-10-27 This is the kind of standard-setting event that can compound quietly across an installed base.
Margins, cash, and what the tape is missing
The margin story is better than the GAAP line suggests but not as clean as the adjusted headline. Adjusted gross margin was 53%, down 30 basis points on mix and inflation, while adjusted operating margin rose 170 basis points to 15.9% on volume leverage and modest opex growth. Full-year guidance calls for 110-160 basis points of gross-margin expansion and a 16-16.3% adjusted operating margin. The last filed quarter is a reminder that adjusted numbers flatter the picture: GAAP operating income was $14 million in the last filed quarter, down 22% year over year. Investors are paying for the adjusted recovery, not the GAAP trough.
Valuation is less extreme than it was, but not cheap. At roughly 9.8x trailing revenue, the price-to-revenue multiple sits far below the 28.7x peak set in 2020. The stock has re-rated on the belief that 2027 is the payoff year. That belief is supported by the order book, the BioLife accretion, and the China and analytics momentum. It is not yet supported by equipment revenue, which is why the filtration decline and the delayed onshoring decisions matter. The tape has voted for the recovery; the P&L still has to deliver it.
The quarter is best read as a show-me report. Repligen has earned credibility on consumables, China, and protein analytics. It has not yet earned it on large-scale equipment. If the capital-equipment tap opens in 2027, the >$1 billion revenue guide could prove conservative and the BioLife deal could look cheap. If it does not, the stock's 39% run has borrowed returns from a year that has not started yet. The company is outgrowing its market; the question is whether the market's most cyclical pocket will finally cooperate.